Liver Research最新文献

{"title":"Prevalence, diagnosis, treatment, and associated factors of hepatitis C in the United States from 1999 to 2018: A population-based cross-sectional study","authors":"Congnan Zhang ,&nbsp;Jiahui Lu ,&nbsp;Yajing Zhang ,&nbsp;Pengyuan He ,&nbsp;Jinyu Xia ,&nbsp;Mingxing Huang","doi":"10.1016/j.livres.2022.12.003","DOIUrl":"10.1016/j.livres.2022.12.003","url":null,"abstract":"<div><h3>Background and aim</h3><p>Hepatitis C virus (HCV) infection is one of the major global health challenges, leading to a significant increase in rates of hepatic fibrosis, cirrhosis and hepatocellular carcinoma. A comprehensive nationwide survey of trends in prevalence and associated factors could facilitate preventive behavioral interventions. Herein, we sought to determine prevalence, diagnosis, treatment, and risk factors for HCV infection in the general United States (US) population.</p></div><div><h3>Methods</h3><p>This was a secondary analysis of the publicly available data from the US National Health and Nutrition Examination Survey (NHANES). The prevalence of HCV-RNA-positive (HCV-RNA+) was weighted using patient serum sample data collected from 1999 to 2018. A propensity score matching model was used due to the imbalance in the number of HCV-RNA+ and HCV-RNA-negative (HCV-RNA−) patients. Matched variables included gender, age, educational level, marital status, language, household size, alcohol consumption, smoking, number of family members and family income to poverty ratio.</p></div><div><h3>Results</h3><p>The weighted prevalence of HCV-RNA+ was 1.11% (95% confidence interval (CI): 1.02–1.20), 1.58% (95% CI: 1.42–1.74) for men and 0.67% (95% CI: 0.57–0.77) for women aged 20 years or older in the US from 1999 to 2018. The weighted prevalence of HCV-RNA+ increased from 0.87% (95% CI: 0.62–1.12) in 2013–2014, 0.95% (95% CI: 0.68–1.22) in 2015–2016 to 1.00% (95% CI: 0.72–1.28) in 2017–2018, respectively. In propensity-matched analysis, patients with HCV-RNA+ were more likely to be non-Hispanic black, and have had drug use and blood transfusions. Meanwhile, the weighted diagnostic and treatment rates were 56.27% (95% CI: 50.90–61.64) and 35.40% (95% CI: 27.64–43.16) from 1999 to 2018, respectively.</p></div><div><h3>Conclusions</h3><p>Active HCV infection rate increased between 2013 and 2018, varied by demographic and risk variables. In the direct-acting antiviral era, affordable treatment and universal screening have the potential to improve overall national health.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 4","pages":"Pages 284-288"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000721/pdfft?md5=072044f4c7cd107f75e110a4bfa40c20&pid=1-s2.0-S2542568422000721-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44483873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemical basis of pregnane X receptor activators in the herbal supplement Gancao (licorice)","authors":"Anqi Cheng ,&nbsp;Saifei Lei ,&nbsp;Junjie Zhu ,&nbsp;Jie Lu ,&nbsp;Mary F. Paine ,&nbsp;Wen Xie ,&nbsp;Xiaochao Ma","doi":"10.1016/j.livres.2022.11.007","DOIUrl":"10.1016/j.livres.2022.11.007","url":null,"abstract":"<div><h3>Background and aims</h3><p>The herbal supplement Gancao, also known as licorice, belongs to the genus <em>Glycyrrhiza</em> and has been used worldwide for its hepatoprotective effect. Recent studies have raised concerns about potential herb-drug interactions associated with Gancao via pregnane X receptor (PXR)-mediated induction of hepatic cytochrome P450 3A4 (CYP3A4). The current work aimed to determine the phytochemicals in Gancao that activate PXR and induce CYP3A4.</p></div><div><h3>Methods</h3><p>DPX2 cells were used for cell-based PXR reporter assays. The phytochemicals in Gancao extract were identified using a metabolomics approach. The effects of PXR activators identified from <em>in vitro</em> studies were further investigated in PXR- and CYP3A4-humanized mouse models.</p></div><div><h3>Results</h3><p>Gancao was verified to be a PXR-activating herb. Two major phytochemicals in Gancao, glycyrrhizin (GZ) and glycyrrhetinic acid (GA), did not activate PXR in the cell-based reporter assays. However, glabridin was shown to activate PXR in a dose-dependent manner. <em>In vivo</em> studies confirmed that GZ is not a PXR activator and glabridin is a weak PXR activator. Although GA did not active PXR <em>in vitro</em>, it induced CYP3A4 expression in a PXR-dependent manner in the PXR- and CYP3A4-humanized mice.</p></div><div><h3>Conclusions</h3><p>GZ is not a PXR activator. GA could not activate PXR in cell-based reporter assays but it could activate PXR <em>in vivo</em>. Glabridin is a weak PXR activator. This work provides novel insights into the underlying mechanisms of Gancao-related herb-drug interactions via PXR.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 4","pages":"Pages 251-257"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S254256842200068X/pdfft?md5=bff88fec13aebaa46dadfe043b6ab64e&pid=1-s2.0-S254256842200068X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44955475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenesis of fatty liver diseases and hepatocellular carcinoma","authors":"John Y.L. Chiang,&nbsp;Tiangang Li","doi":"10.1016/j.livres.2022.12.001","DOIUrl":"10.1016/j.livres.2022.12.001","url":null,"abstract":"","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 4","pages":"Pages 201-202"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000708/pdfft?md5=bf3f23283e024892c75b7cd184898a22&pid=1-s2.0-S2542568422000708-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44405448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis","authors":"Nancy Magee ,&nbsp;Forkan Ahamed ,&nbsp;Natalie Eppler ,&nbsp;Elizabeth Jones ,&nbsp;Priyanka Ghosh ,&nbsp;Lily He ,&nbsp;Yuxia Zhang","doi":"10.1016/j.livres.2022.11.001","DOIUrl":"10.1016/j.livres.2022.11.001","url":null,"abstract":"<div><h3>Background and aim</h3><p>Non-alcoholic fatty liver disease (NAFLD) is becoming a leading cause of chronic liver disease worldwide. The molecular events that influence disease progression from non-alcoholic fatty liver (NAFL) to aggressive non-alcoholic steatohepatitis (NASH) remain incompletely understood, leading to lack of mechanism-based targeted treatment options for NASH. This study aims to identify early signatures associated with disease progression from NAFL to NASH in mice and humans.</p></div><div><h3>Materials and methods</h3><p>Male C57BL/6J mice were fed a high-fat, -cholesterol, and -fructose (HFCF) diet for up to 9 months. The extent of steatosis, inflammation, and fibrosis was evaluated in liver tissues. Total RNA sequencing (RNA-seq) was conducted to determine liver transcriptomic changes.</p></div><div><h3>Results</h3><p>After being fed the HFCF diet, mice sequentially developed steatosis, early steatohepatitis, steatohepatitis with fibrosis, and eventually spontaneous liver tumor. Hepatic RNA-seq revealed that the key signatures during steatosis progression to early steatohepatitis were pathways related to extracellular matrix organization and immune responses such as T cell migration, arginine biosynthesis, C-type lectin receptor signaling, and cytokine-cytokine receptor interaction. Genes regulated by transcription factors forkhead box M1 (FOXM1) and negative elongation factor complex member E (NELFE) were significantly altered during disease progression. This phenomenon was also observed in patients with NASH.</p></div><div><h3>Conclusions</h3><p>In summary, we identified early signatures associated with disease progression from NAFL to early NASH in a mouse model that recapitulated key metabolic, histologic, and transcriptomic changes seen in humans. The findings from our study may shed light on the development of novel preventative, diagnostic, and therapeutic strategies for NASH.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 4","pages":"Pages 238-250"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977163/pdf/nihms-1856467.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9372128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target","authors":"Hanqing Chen","doi":"10.1016/j.livres.2022.09.003","DOIUrl":"10.1016/j.livres.2022.09.003","url":null,"abstract":"<div><p>Non-alcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide, and is closely associated with the increased risk of the prevalence of obesity and diabetes. NAFLD begins with the presence of &gt;5% excessive lipid accumulation in the liver, and potentially develops into non-alcoholic steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma. Therefore, insight into the pathogenesis of NAFLD is of key importance to its effective treatment. Iron is an essential element in the life of all mammalian organisms. However, the free iron deposition is positively associated with histological severity in NAFLD patients due to the production of reactive oxygen species via the Fenton reaction. Recently, several iron metabolism-targeted therapies, such as phlebotomy, iron chelators, nanotherapeutics. and ferroptosis, have shown their potential as a therapeutic option in the treatment of NAFLD and as a clinical strategy to intervene in the progression of NAFLD. Herein, we review the recent overall evidence on iron metabolism and provide the mechanism of hepatic iron overload-induced liver pathologies and the recent advances in iron metabolism-targeted therapeutics in the treatment of NAFLD.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 4","pages":"Pages 203-213"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000459/pdfft?md5=f2e918de620676f2d2273542e7b15c28&pid=1-s2.0-S2542568422000459-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43790882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to <’Deficiency of pyruvate dehydrogenase kinase 4 sensitizes mouse liver to diethylnitrosamine and arsenic toxicity through inducing apoptosis’>Liver Research volume 2 (2018) 100–107","authors":"Jonathan Choiniere, Matthew Junda Lin, Li Wang, Jianguo Wu","doi":"10.1016/j.livres.2022.11.004","DOIUrl":"https://doi.org/10.1016/j.livres.2022.11.004","url":null,"abstract":"","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48282966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer","authors":"Jia-Ren Wang ,&nbsp;Rui-Ning Li ,&nbsp;Chao-Yi Huang ,&nbsp;Chang Hong ,&nbsp;Qi-Mei Li ,&nbsp;Lin Zeng ,&nbsp;Jing-Zhe He ,&nbsp;Cheng-Yi Hu ,&nbsp;Hao Cui ,&nbsp;Li Liu ,&nbsp;Lu-Shan Xiao","doi":"10.1016/j.livres.2022.05.004","DOIUrl":"10.1016/j.livres.2022.05.004","url":null,"abstract":"<div><h3>Background and aim</h3><p>Immune checkpoint inhibitors (ICIs) are widely used in the treatment of liver cancer. However, the interaction with other drugs may change the efficacy of ICIs. Few studies investigated the effects of antibiotics (ATBs) on the efficacy of immunotherapy and the survival of patients with primary liver cancer receiving immunotherapy. This study aimed to explore the impact of ATBs on the efficacy of immunotherapy in patients with primary liver cancer.</p></div><div><h3>Methods</h3><p>In total, 215 patients with primary liver cancer who received ICIs from June 2018 to October 2020 were included for retrospective analysis. The progression-free survival (PFS), disease control rate (DCR), and overall survival (OS) were compared between patients treated with and without ATBs within 30 days before and after immunotherapy.</p></div><div><h3>Results</h3><p>No significant differences in PFS (<em>P</em> = 0.376) and OS (<em>P</em> = 0.121) were found between patients treated with and without ATBs. Univariate and multivariate analyses showed that using ATBs was not associated with PFS, DCR, and OS.</p></div><div><h3>Conclusion</h3><p>The use of ATBs within 30 days before and after immunotherapy in patients with primary liver cancer had no adverse effects on PFS, DCR, and OS.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 175-180"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000228/pdfft?md5=d885f83d21f0312736ae12d0b3bf3841&pid=1-s2.0-S2542568422000228-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45562982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of low-dose rifampicin in patients with benign intrahepatic cholestasis","authors":"Xiaoyan Guo,&nbsp;Xinhua Li,&nbsp;Ying Yan,&nbsp;Huijuan Cao,&nbsp;Yufeng Zhang,&nbsp;Jing Lai","doi":"10.1016/j.livres.2022.08.006","DOIUrl":"10.1016/j.livres.2022.08.006","url":null,"abstract":"<div><h3>Background and aim</h3><p>Some previous studies supported that rifampicin was an effective treatment for benign intrahepatic cholestasis. However, the efficacy and safety of rifampicin remain unclear. Therefore, this study aimed to evaluate its efficacy and safety on benign intrahepatic cholestasis.</p></div><div><h3>Methods</h3><p>A retrospective, single-center, observational study was conducted on patients diagnosed with benign intrahepatic cholestasis between 2019 and 2021, who were administered 150 mg of rifampicin orally once a day. We collected and analyzed the data at baseline and post-treatment, including total bilirubin (TBIL), direct bilirubin (DBIL), total bile acid (TBA), gamma-glutamyl transferase (GGT), alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase levels. Statistical analysis was performed using appropriate tests.</p></div><div><h3>Results</h3><p>A total of 17 rifampicin-treated patients were enrolled in the study from January 2019 to January 2021. Among them, 14 patients (82%) improved, with significantly decreased TBIL, DBIL, and TBA levels after 3 weeks of treatment (all <em>P</em> &lt; 0.05), whereas the remaining 3 had no improvement. Moreover, GGT levels of the former were significantly lower than those of the latter (34 (12–227) U/L <em>vs</em>. 244 (76–293) U/L, <em>P</em> = 0.023) at baseline. No severe adverse effect was observed during treatment.</p></div><div><h3>Conclusions</h3><p>Low-dose rifampicin (150 mg per day) was an effective and safe treatment for benign intrahepatic cholestasis. Low GGT level at baseline and a significant decrease of TBIL, DBIL, and TBA levels within the first 3 weeks of treatment may lead to the good curative effect.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 181-185"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000423/pdfft?md5=f03f83d7ab84e7b61cd7ef305c3d4f49&pid=1-s2.0-S2542568422000423-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46411178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berberine enhances the anti-hepatocellular carcinoma effect of NK92-MI cells through inhibiting IFN-gamma-mediated PD-L1 expression","authors":"Kunyuan Wang ,&nbsp;Chengxin Gu ,&nbsp;Ganxiang Yu ,&nbsp;Jiaen Lin ,&nbsp;Zhilei Wang ,&nbsp;Qianting Lu ,&nbsp;Yangzhi Xu ,&nbsp;Dan Zhao ,&nbsp;Xiaofeng Jiang ,&nbsp;Weijian Mai ,&nbsp;Shiming Liu ,&nbsp;Hui Yang","doi":"10.1016/j.livres.2022.08.003","DOIUrl":"10.1016/j.livres.2022.08.003","url":null,"abstract":"<div><h3>Background and aims</h3><p>Berberine is one of the most promising clinically tested natural alkaloids, and immunotherapy using natural killer (NK) cells is a potentially effective treatment for hepatocellular carcinoma (HCC). This study aims to elucidate the effect of berberine on the anti-HCC effect of NK92-MI cells.</p></div><div><h3>Materials and methods</h3><p>Human HCC SMMC-7721 and Hep3B cells were co-incubated with NK92-MI cells, berberine (60 or 80 μmol/L), or their combination for 36 h. To evaluate the killing effect of NK92-MI cells on HCC cells, the release of lactate dehydrogenase (LDH) in HCC cells was measured. The anti-tumor effects of berberine, NK92-MI cells, and their combinations were evaluated by MTS, EdU, Tunel, and Western blot assays. A male BALB/c nude mouse subcutaneous tumor model was used to investigate the anti-HCC effect of berberine and NK92-MI cells <em>in vivo</em>.</p></div><div><h3>Results</h3><p>The LDH assay showed that berberine enhanced the cytotoxicity of NK92-MI cells on HCC cells. The combination of berberine and NK92-MI cells demonstrated more obvious anti-HCC effect than did the berberine or NK92-MI single treatment in inhibiting cell proliferation and inducing apoptosis both <em>in vitro</em> and <em>in vivo</em>. Mechanistically, the expression of programmed cell death-ligand 1 (PD-L1) in HCC cells was upregulated after co-culture with NK-92MI cells. PD-L1 expression was knocked down, thereby inhibiting the proliferation and promoting apoptosis of HCC cells, and inhibited by berberine that blocked the secretion of interferon gamma (IFN-γ), thereby enhancing the anti-tumor effect of NK92-MI cells.</p></div><div><h3>Conclusions</h3><p>Current data show that the immunomodulatory role of berberine is to enhance the cytotoxic effect of NK92-MI cells and inhibit tumor immune escape by reducing the expression of PD-L1. Our study provides a rationale for the clinical application of berberine in combination with NK cells for the treatment of HCC.</p></div>","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 167-174"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568422000393/pdfft?md5=9a6fe0da7ef4d2aef15efde414e3c243&pid=1-s2.0-S2542568422000393-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55273550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wu Mengchao: A blade warrior against liver cancer","authors":"Tian Yang,&nbsp;Qi Zhang,&nbsp;Ming-Da Wang,&nbsp;Feng Shen","doi":"10.1016/j.livres.2021.11.002","DOIUrl":"10.1016/j.livres.2021.11.002","url":null,"abstract":"","PeriodicalId":36741,"journal":{"name":"Liver Research","volume":"6 3","pages":"Pages 130-131"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2542568421000611/pdfft?md5=899968fc321a220f5e08146923b165b7&pid=1-s2.0-S2542568421000611-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47396876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}